Researchers profiled cancer gene mutations, expression, protein patterns, and other features in 23 recurrent or metastatic cases of olfactory neuroblastoma.
The work offers a proof of concept for the notion that dynamic models of signaling could serve as more effective biomarkers than discrete molecular markers.
Using funds from the California precision medicine initiative, the group will use its bioinformatics expertise to match patients to treatments in pediatric clinical trials.
Entrectinib is Ignyta's lead product that the biotech is investigating in patients with tumors characterized by TrkA, TrkB, TrkC, ROS1, and ALK markers.
NEW YORK (Genomeweb) — A study comprehensively analyzing the genomes of more than 1,500 neuroblastoma cases has better determined the prognostic significance of ALK mutations and other alterations in neuroblastoma, and has biochemically investigated many of these variants to determine which ones
NEW YORK (GenomeWeb News) — The New York Genome Center and The Sohn Conference Foundation said today that they have launched The Sohn Collaborative for Pediatric Cancer Research.
Researchers from several European institutions have used a clinical trial of children with stage IV neuroblastoma to test prospectively whether varying levels of several mRNA markers could stratify patients according to their outcomes.
